e programma di attività 2013 2012 - cpo.it · 3.004 Monitoraggio di indicatori di qualità della...

S c h e d e e p r o g r amma d i a t t i v i t 2 0 1 3 R e l a z i o n e d i a t t i v i t 2 0 1 2 E l e n c o pubb l i c a z i o n i 2 0 1 2

I N D I C E

Schede di attivit 2013

Prevenzione pr imar ia e documentazione sul la cancerogenesi pag. 6

Registro Tumori pag. 23

Prevenzione secondar ia pag. 65

Epidemiologia ezio logica pag. 139

Epidemiologia c l in ica pag. 206

Rete Oncologica pag. 242

Programma di attivit per il 2013 pag. 249

Relazione di attivit per il 2012 pag. 268

Elenco pubblicazioni 2012 pag. 298

Indice schede di attivit 2013

Prevenzione primaria e documentazione sulla cancerogenesi 1.001 Prevenzione primaria: stima dei casi potenzialmente prevenibili in Piemonte mediante attivit di

prevenzione primaria. Revisione dellefficacia di interventi di prevenzione primaria per modificare abitudini e stili di vita a rischio ..................................................................................................................... 6

1.002 Archivio cancerogeni ................................................................................................................................... 8 1.003 Prevenzione primaria: progetto per la prevenzione e riduzione del tabagismo in Piemonte....................... 10 1.004 DIANA (Dieta e Androgeni)-5 studio randomizzato e controllato per valutare l'efficacia della dieta e

dell'attivit fisica nella riduzione del rischio di recidiva di carcinoma mammario sulla base di parametri ormonali e/o metabolici ............ .................................................................................................................. 13

1.007 STI.VI.: studio pilota di valutazione di interventi di prevenzione primaria nella popolazione invitata nei programmi di screening mammografico e colorettale. ............................................................................... 18

1.008 In rete per un ambiente sanitario senza fumo............................................................................................. 21

Registro Tumori 2.001 Incidenza dei tumori nella popolazione piemontese ................................................................................... 23 2.002 Sopravvivenza: aggiornamento del follow-up, analisi, divulgazione dei risultati e contributi a studi

collaborativi.................................................................................................................................................. 27 2.003 Registrazione della mortalit tumorale nella Regione Piemonte ............................................................... 30 2.006 Follow-up della coorte EPIC-Torino: end point di stato in vita, causa di morte e incidenza tumorale......... 32 2.007 Registro Tumori Infantili .............................................. ............................................................................... 34 2.008 Incidenza dei tumori negli adolescenti (15-19 anni) in Piemonte ............................................................... 40 2.010 Realizzazione e manutenzione sistema informatico dell'unit di epidemiologia ........................................ 422.011 Qualit di vita lungosopravvissuti dopo tumore infantile ............................................................................ 43 2.016 Produzione dindicatori di prevalenza dei tumori nella popolazione torinese ............................................. 45 2.023 I tumori nella popolazione immigrata in Piemonte dallestero. Stima della frequenza nel prossimo

decennio...................................................................................................................................................... 46 2.024 Progetto EUNICE (sopravvivenza di periodo) ............................................................................................ 48 2.029 Indicatori di processo e di risultato dei programmi di screening ................................................................ 50 2.030 Progetto EUROCOURSE (UE, 7th Framework Programme. ERAnet) ...................................................... 52 2.031 Incidenza dei tumori nella provincia di Biella e Vercelli.............................................................................. 54 2.032 Stima dell'incidenza, prevalenza e sopravvivenza dei principali tumori in Piemonte ................................ 58 2.033 Classificazione TNM dei tumori maligni, VII edizione 2009: edizione italiana e sua promozione............... 60 2.034 PanCareSurFup Follow-up e assistenza a lungo termine dei sopravvissuti a tumore in et pediatrica

(et 0-19 anni) ............................................................................................................................................ 61 2.035 Estensione della registrazione dei tumori alla Regione Piemonte ............................................................. 63

Prevenzione secondaria 3.001 Programma regionale di screening dei tumori della cervice uterina e della mammella ............................. 65 3.001bis Programma formativo di screening dei tumori del collo dellutero, della mammella e del colon retto nella Regione Piemonte. Formazione teorica e pratica per il personale addetto ai programmi di screening per lanno 2012-2013 ........................................................................................................................................ 68 3.002 Valutazione di processo e impatto per lo screening del cervicocarcinoma ................................................ 71 3.003 Attivazione nei programmi di screening mammografico regionali di un sistema di valutazione corrente e di progetti di promozione della qualit ....................................................................................................... 75 3.004 Monitoraggio di indicatori di qualit della diagnosi e del trattamento del carcinoma mammario ............... 78 3.005 Studio multicentrico controllato e randomizzato di valutazione di efficacia dello screening

sigmoidoscopio nella prevenzione del carcinoma colorettale (SCORE) ..................................................... 81 3.005All. Banca biologica dei polipi colorettali .......................................................................................................... 83 3.006 Costi e benefici dellintroduzione di nuove tecnologie nello screening del cervicocarcinoma ................... 86 3.007 Promozione della qualit della lettura citologica e del secondo livello nei programmi di screening del

cervicocarcinoma ....................................................................................................................................... 91 3.008 Confronto tra diverse politiche di screening per il cancro colorettale (CCR) progetto dimostrativo a

Torino e studio multicentrico italiano .......................................................................................................... 94 3.008All. Valutazione di impatto di diverse strategie di screening dei tumori del colon-retto. Follow-up degli studi

SCORE2 e SCORE3 ................................................................................................................................. 97 3.010 Programma regionale di screening dei tumori colorettali .......................................................................... 99

3.011 Confronto di diverse metodiche di screening dei tumori colorettali. Valutazione della colonscopia come test di screening ......................................................................................................................................... 101

3.012 Costruzione di un database di dati individuali per la valutazione dello screening mammografico in Europa / Progetto DWH nazionale di screening ........................................................................................ 103

3.014 Realizzazione di una campagna di screening dei tumori del collo dell'utero (Pap-test) nel Cantone di Zenica-Duboj (Bosnia) ................................................................................................................................ 105

3.016 Valutazione dellimpatto sulla mortalit dei programmi di screening mammografici a Torino e in Italia .... 107 3.018 Prevenzione Serena. Integrazione anche nella prevenzione. La prevenzione del tumore del collo

dellutero...................................................................................................................................................... 109 3.021 Valutazione dellattivit di screening di popolazione nelle province di Novara e Verbano Cusio Ossola.. 111 3.022 Studio delle dinamiche di trasmissione dellinfezione da HPV per stimare limpatto della vaccinazione

per alcuni tipi di HPV sullo screening cervicale .......................................................................................... 112 3.024 Interazione dello screening cervicale con la vaccinazione per alcuni tipi di papillomavirus umano nella

prevenzione del cancro della cervice uterina ............................................................................................. 113 3.025 Triage con DNA fecale nello screening dei tumori colorettali .................................................................... 115 3.026 Utilizzo della colonscopia virtuale come test di screening dei tumori colorettali. Confronto con la

sigmoidoscopia ........................................................................................................................................... 117 3.027 Interventi per ridurre le disuguaglianze nellaccesso allo screening, incrementare la partecipazione nella

popolazione generale ed in sottogruppi specifici ........................................................................................ 120 3.028 Service per la valutazione di processo e di impatto dei programmi regionali di screening mammografico,

cervicale e del colon retto ........................................................................................................................... 123 3.030 Progetto pilota di utilizzo del test per il DNA di papillomavirus umano come test primario di screening

per i precursori del cancro cervicale ........................................................................................................... 125 3.032 Aderenza allo screening citologico fra le donne albanesi .......................................................................... 127 3.033 Progetto Proteus Donna: lettura a distanza delle mammografie digitali e studio sperimentale

randomizzato sull'utilizzo della tomosintesi (DBT) per lo screening del tumore della mammella ............... 129 3.034 Implementazione dei programmi di screening: analisi delle barriere e dei fattori facilitanti, modificabili e

non .............................................................................................................................................................. 131 3.035 Individuazione delle disuguaglianze in salute e creazione di conseguenti modelli di azioni di

sorveglianza e contrasto ......................................................................... .................................................. 133 3.036 Lo screening dei tumori e la diagnosi precoce nei paesi del mediterraneo ................................................ 135 3.037 Valore predittivo di criteri combinati per la personalizzazione dello screening mammografico e nuove

opportunit offerte da marcatori molecolari circolanti ................................................................................. 137

Epidemiologia eziologica 4.001 Rischio di mesotelioma maligno ed esposizione ambientale e lavorativa ad amianto................................. 139 4.002 Studi di coorte su particolari gruppi di esposti ad amianto ......................................................................... 141 4.003 Incidenza, eziologia e prognosi dei mesoteliomi in Piemonte .................................................................... 144 4.004 Alimentazione e rischi di cancro: studio prospettico EPIC ......................................................................... 147 4.006 Studio europeo sui tumori rari .................................................................................................................... 152 4.009 Studio multicentrico italiano sull'eziologia dei tumori infantili linfoemopoietici e dei neuroblastomi

(SETIL) ....................................................................................................................................................... 154 4.018 Studio GEM: un modello per la suscettibilit genetica, fase 2: sopravvivenza dei soggetti GEM ............. 156 4.021 Studio di coorti di lavoratori dell'industria della gomma .............................................................................. 158 4.023 Biologia molecolare dei mesoteliomi maligni .............................................................................................. 160 4.025 Tumori dell'endometrio, alimentazione, peso corporeo e interazioni geni-ambiente: uno studio

collaborativo in Italia e negli USA ............................................................................................................... 162 4.028 Fattori ambientali e suscettibilit genetica nell'eziologia dei tumori del capo collo: studio epidemiologico

multicentrico europeo ................................................................................................................................. 164 4.030 Indagine sui fattori di rischio per il cancro della mammella nella popolazione femminile invitata allo

screening mammografico FriCaM ........................................................................................................... 167 4.033 Coorte di nuovi nati basata su web. il progetto NINFEA ............................................................................. 168 4.042 GENE-RAD: studio multicentrico europeo sul rischio di tumore maligno della mammella associato a

radiazione in et giovanile e caratteristiche genetiche .............................................................................. 170 4.044 Aggiustamento bayesiano empirico per confronti multipli .......................................................................... 172 4.045 Studio multicentrico italiano sulla mortalit nellobesit grave ................................................................... 174 4.046 Rilevamento dello stato di integrazione di papillomavirus di ceppo 16 in lesioni cervicali pre-

neoplastiche confermato con DIPS-PCR e sequenziamento ..................................................................... 176

4.050 Studio di coorte su pazienti affetti da obesit severa o complicata afferenti lospedale San Giuseppe, Piancavallo ................................................................................................................................................. 178

4.051 Studio caso-controllo sui determinanti genetici e ambientali del tumore della vescica .............................. 1794.053 Synergy ...................................................................................................................................................... 181 4.054 Tumore del testicolo: Studio caso-controllo in Piemonte e studi collaborativi ............................................ 183 4.055 Frequenza e infettivit di HCV-RNA nei linfociti di soggetti con patologie non correlate ad HCV .............. 185 4.057 Studio delle dinamiche di trasmissione della tubercolosi per stimare Limpatto dellimmigrazione e delle

misure di prevenzione ................................................................................................................................. 187 4.058 Studio europeo multicentrico di coorte sugli effetti di lungo termine dellinquinamento atmosferico

(ESCAPE). Centro di Torino ....................................................................................................................... 188 4.060 Metilazione del DNA nel tessuto prostatico tumorale e non tumorale come marker di sviluppo e

progressione del tumore della prostata ....................................................................................................... 190 4.061 MOBI-KIDS: Rischio di tumore cerebrale da esposizione alle radiofrequenze durante linfanzia e

ladolescenza: uno studio multicentrico internazionale ............................................................................... 192 4.062 Utilizzo della metformina e rischio di tumori nella popolazione torinese .................................................... 193 4.063 Studio pilota multicentrico sugli effetti di breve termine dellinquinamento atmosferico mediante utilizzo

di dati correnti di accesso in Pronto Soccorso. .......................................................................................... 195 4.064 Studio multicentrico internazionale IARC sulla mortalit dei lavoratori della gomma.................................. 1974.065 Studio Piccoli+: arruolamento e sorveglianza epidemiologica di una coorte nazionale di nati.................... 198 4.066 Stato di metilazione di HLA-G, infezione da HPV e neoplasie cervicali: studio caso-controllo condotto su

una popolazione brasiliana ......................................................................................................................... 199 4.067 Rilevazione di anticorpi anti-IFI16 mediante ELISA: associazioni sierologiche e cliniche nei pazienti

affetti da LUPUS eritematoso sistemico................................. .................................................................... 201 4.068 Infezione virale immunodepressione nell'eziologia dei Tumori cutanei nei soggetti immunodepressi ........ 203 4.069 Applicazione dei metodi dell'Inferenza causale ................................. ........................................................ 205

Epidemiologia clinica 5.002 Evidence-Based Medicine e qualit dell'assistenza ospedaliera ................................................................ 206 5.003 Chirurgia radicale verso conservativa per il tumore dello stomaco e consulenza ad altri progetti di

epidemiologia clinica in ambito gastroenterologico ..................................................................................... 209 5.006 Linee Guida regionali per loncologia .......................................................................................................... 211 5.008 Progetto di ricerca-intervento triennale: la qualit in oncologia .................................................................. 214 5.011 Studio HOT (Hormones Opposed by Tamoxifen) ....................................................................................... 217 5.016 Centro per i trial clinici in oncologia e progetto EPICLIN ............................................................................ 219 5.017 Descrizione dellattivit di ricovero e della mobilit sanitaria nell'area del Piemonte Orientale (quadrante

2), analisi dei dati rilevati con la Scheda di Dimissione Ospedaliera (SDO) .............................................. 2265.019 Valutazione economica e di qualit negli studi di epidemiologia clinica .................................................... 228 5.025 Valutazione degli esiti estetici nelle pazienti operate per lesioni mammarie ............................................. 232 5.026 Studio randomizzato placebo controllato sulla prevenzione di ricorrenze con tamoxifen a basse dosi in

donne con neoplasia intraepiteliale della mammella ................................................................................. 236 5.027 Ecografia toracica nei pazienti con dispnea nel Dipartimento di Emergenza ............................................ 2385.028 Registro Trapianti Renali dellAOU Maggiore della Carit di Novara.......................................................... 240

Rete Oncologica 6.001 Uso dei dati epidemiologici per la programmazione e la valutazione dellassistenza oncologica................ 242 6.003 Valutazione degli esiti del programma quadriennale di formazione permanente e aggiornamento

nell'ambito della Rete Oncologica sul carcinoma mammario ...................................................................... 245 6.004 Programma quadriennale di formazione permanente e aggiornamento nell'ambito della Rete

Oncologica sul carcinoma mammario. Progetto di creazione di un sito formativo di presentazione di casi clinici e materiale bibliografico relativo suddiviso per patologie oncologiche e collegato con il sito web della Rete Oncologica. ................................................................................................................................ 248

Current research projects: table of contents

Primary prevention and documentation on carcinogens1.001 Primary prevention: cancer cases potentially preventable in Piedmont and review of the effectiveness of

intervention ................................................................................................................................................. 6 1.002 Database of carcinogenic agents ............................................................................................................... 8 1.003 Primary prevention: planning of anti smoking interventions in Piedmont ................................................... 10 1.004 DIANA (Diet and Androgens)-5 randomized controlled trial to test the efficacy of dietary change and

physical activity to prevent or delay the development of recurrences in breast cancer (BC) patients estimated to be at high risk based on their hormonal or metabolic milieu................................................... 13

1.007 STI.VI.: pilot study evaluation of interventions for primary prevention programs in the population invited to mammography and colorectal cancer screening programs. ................................................................... 18

1.008 Smoke-free hospital network....................................................................................................................... 21

Cancer registries2.001 Cancer incidence in Piedmont .................................................................................................................... 23 2.002 Survival: updating the follow-up, the analysis, and the results dissemination; contribution to

collaborative studies .................................................................................................................................. 27 2.003 Cancer mortality registration in Piedmont ................................................................................................. 30 2.006 Turin EPIC cohort follow-up: causes of death and cancer incidence ........................................................ 32 2.007 Childhood cancer registry ......................................................................................................................... 34 2.008 Cancer incidence in adolescent (15-19 years) .......................................................................................... 40 2.010 Design, implementation and maintenance of the epidemiology unit computing system............................ 42 2.011 Health related quality of life among longterm survivors after a childhood cancer ..................................... 432.016 Cancer prevalence in Turin residents ....................................................................................................... 45 2.023 Cancer in migrant populations in Turin. Estimate of the frequency in the next decade............................. 46 2.024 EUNICE project (period survival) .............................................................................................................. 48 2.029 Early and impact indicators for screening programmes ............................................................................ 50 2.030 Optimisation of the Use of Registres for Scientific Excellence in Research ............................................. 52 2.031 Cancer incidence in province of Biella and Vercelli......................................... ......................................... 54 2.032 Incidence, prevalence and survival estimates of principal cancers in Piedmont ...................................... 582.033 TNM classification of malignant tumours, VII edition 2009: Italian edition and its promotion ................... 60 2.034 PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies .................................. 61 2.035 Extension of cancer registration in the Piedmont Region .......................................................................... 63

Secondary prevention 3.001 Cervical and breast cancer screening regional programme ....................................................................... 65 3.001bis Breast-cervical and colorectal cancer screening educational programme in Piedmont. Theoretical and

practical training for the staff assigned to screening programmes for the year 2012-2013 ....................... 68 3.002 Process and impact evaluation of cervical cancer screening programmes ............................................... 713.003 Evaluation and quality assurance of breast cancer screening programmes in Piedmont .......................... 75 3.004 Monitoring diagnosis and treatment of screen-detected breast cancer ..................................................... 78 3.005 Multicentre randomized controlled trial of once-only sigmoidoscopy screening for colorectal cancer

(SCORE) .................................................................................................................................................... 81 3.005All. Colorectal polyps biological databank .............................................................................................. 83 3.006 Costs and benefits of new technologies in cervical cancer screening ....................................................... 86 3.007 Quality assurance for smear interpretation, histology and colposcopy in cervical cancer screening

programmes ............................................................................................................................................... 91 3.008 Comparing risk-benefit ratio and costs of different screening strategies for colorectal cancer. Turin pilot

project and Italian multicentre study ........................................................................................................... 94 3.008All. Evaluating the impact of different screening strategies for colorectal cancer ............................................. 973.010 Colorectal cancer screening ...................................................................................................................... 99 3.011 Assessing the role of colonoscopy in screening for colorectal cancer ....................................................... 101 3.012 European breast cancer screening evaluation database / National cancer screening datawarehouse ..... 103 3.014 Implementation of a cervical cancer screening pilot project in Zenica Duboj Canton (Bosnia Erzegovina)... 105 3.016 Impact on mortality of breast cancer screening programmes .................................................................... 107 3.018 Approaching a multicultural prevention in cervical cancer screening ......................................................... 109 3.021 Assessment of population based cancer screening in the provinces of Novara and Verbano Cusio

Ossola ......................................................................................................................................................... 111

3.022 Investigation of HPV transmission dynamics in order to estimate the impact of vaccination for some HPV types on cervical screening ................................................................................................................ 112

3.024 Interaction between cervical screening and vaccination for some types of human papillomavirus in preventing cervical cancer ......................................................................................................................... 113

3.025 Assessing the role of fecal DNA testing in selecting FOBT positive subjects with advanced colonic neoplasia .................................................................................................................................................... 115

3.026 Assessing the role of virtual colonoscopy in screening for colorectal cancer. A comparison with sigmoidoscopy ............................................................................................................................................ 117

3.027 Interventions to reduce the inequalities in accessing screening and to increase the participation in the target population, with specific focus on disadvantaged sub-groups .......................................................... 120

3.028 Implementation of a regional service for monitoring the cancers detected by mammography, cervical and colorectal screening programmes in Piedmont .................................................................................... 123

3.030 Pilot project on the use of Human Papillomavirus DNA testing as primary screening test for cervical cancer precursors ....................................................................................................................................... 125

3.032 Cervical cancer screening uptake among Albanian women in Piedmont ................................................... 1273033 Proteus Donna project. Regional digital mammography system and reading protocol with transmission

of images; randomized trial on the use of tomosinthesis (DBT) for breast cancer screening.................... 129 3.034 Cancer screening implementation: analysis of barriers and removable obstacles in their implementation. 131 3.035 Implementation of models of surveillance and reduction of inequalities in accessing health and cancer

screening services ..................................................................................................................................... 133 3.036 Cancer screening and early diagnosis in mediterranean countries ............................................................ 135 3.037 Predictive value of combined criteria to tailor breast cancer screening and new opportunities from

circulating markers....................................................................................................................................... 137

Aetiology 4.001 Risk of malignant mesothelioma after environmental and occupational exposure to asbestos .................. 139 4.002 Cohort studies on high risk groups following exposure to asbestos ........................................................... 141 4.003 Incidence, etiology and prognosis of mesothelioma in Piedmont ............................................................... 144 4.004 Diet and risks of cancer: EPIC prospective investigation ............................................................................ 147 4.006 Rare cancers in Europe .............................................................................................................................. 152 4.009 Italian multicentric study on etiological factors for childhood leukemia, lymphoma and neuroblastoma

(SETIL)........................................................................................................................................................ 154 4.018 GEM study: a model for genetic susceptibility, phase two: GEM subjects survival ................................... 1564.021 Cohort mortality study on rubber workers .................................................................................................. 158 4.023 Molecular biology of malignant mesothelioma ........................................................................................... 160 4.025 Endometrial cancer, diet, body weight, and gene-environment interactions: a collaborative study in Italy

and the United States ................................................................................................................................. 162 4.028 Environmental factors and genetic susceptibility in the aetiology of head and neck cancers: a

multicentric European epidemiological study .............................................................................................. 164 4.030 Risk factors for breast cancer among women invited for mammography screening: a population survey 167 4.033 Web-based birth cohort: the NINFEA project ............................................................................................. 168 4.042 GENE-RAD-Risk radiation exposures at an early age: impact of genotype on breast cancer risk. A

European multicentre study ........................................................................................................................ 170 4.044 Empirical bayes adjustments for multiple comparisons ............................................................................. 172 4.045 Italian multicentric mortality study of severely obese patients .................................................................... 174 4.046 Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and

confirmation by DIPS-PCR and sequencing ............................................................................................... 176 4.050 Cohort study of patients with severe or compicated obesity, recruited at San Giuseppe hospital,

Piancavallo.................................................................................................................................................. 178 4.051 Turin bladder cancer case control study ..................................................................................................... 179 4.053 Synergy ....................................................................................................................................................... 181 4.054 Testicular cancer: Case-control study in the Piedmont region and collaborative studies............................ 183 4.055 HCV-RNA frequency and infectivity in perypheral blood lymphocytes of subjects free of HCV related

pathologies................................................................................................................................................... 185 4.057 Investigation of tuberculosis transmission dynamics in order to estimate the impact of immigration and

prevention measures .................................................................................................................................. 187 4.058 European study of Cohorts for air pollution effects Turin area ................................................................. 188

4.060 DNA methylation in prostate neoplastic and non-neoplastic tissue as a marker of prostate cancer development and progression ..................................................................................................................... 190

4.061 MOBI-KIDS: Brain cancer risk from exposure to radiofrequency fields in childhood and adolescence: a multicentric international study .................................................................................................................... 192

4.062 Use of metformin and the risk of cancer in a population based study ....................................................... 193 4.063 Multicentric pilot study on short term effects of air pollution using administrative data on Emergency

Department visits. ....................................................................................................................................... 195 4.064 IARC multi-centric international study on mortality of rubber workers ........................................................ 197 4.065 Piccoli+: a national birth cohort ................................................................................................................... 198 4.066 HLA-G promoter methylation status, HPV infection and cervical neoplasia: a Brazilian case-control

study ........................................................................................................................................................... 199 4.067 Detection of anti-IFI16 antibodies by ELISA: clinical and serological association in Systemic Lupus

Erythematosus............................................................................................................................................. 201 4.068 Viral infection and immunodepression in the etiology of skin tumor in immuno compromised subjects .... 203 4.069 Applied causal inference ............................................................................................................................ 205

Clinical epidemiology 5.002 Evidence-Based Medicine and quality of hospital care ............................................................................... 206 5.003 Conservative versus radical surgery for stomach cancer and clinical epidemiology consulting in other

projects in gastroenterology ........................................................................................................................ 209 5.006 Regional guidelines for oncology ................................................................................................................ 211 5.008 A project of research-intervention on quality of care in oncology ............................................................... 214 5.011 The HOT trial (Hormones Opposed by Tamoxifen) .................................................................................... 217 5.016 Centre for clinical trials in oncology and the EPICLIN project ..................................................................... 219 5.017 Patterns of hospitalisation in North-Eastern Piedmont use of hospital discharge data ............................ 226 5.019 Economic evaluation and quality assessment in clinical epidemiology studies .......................................... 2285.025 Evaluation of cosmetic results in patients surgical treated for mammary lesion ......................................... 232 5.026 Randomized controlled trial on prevention of recurrences by low dose tamoxifen in women with breast

intra-epithelial neoplasia ............................................................................................................................. 236 5.027 Lung ultrasound for acute dyspnoea in Emergency Department ............................................................... 238 5.028 Hospital based Renal transplant registry of Novara teaching hospital........................................................ 240

Oncologic network 6.001 Using epidemiologic data for health care planning and evaluation in oncology. ......................................... 2426.003 Quality indicators in multidisciplinary training for senologist projet (FIM): experience of Piedmont region.. 245 6.004 Multidisciplinary training for Senologists...................................................................................................... 248

Prevenzione primaria e documentazione sulla cancerogenesi

Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in PiemonteScheda: 1.001

!"#$%&'%(($

) *$!"'!(

#$(($+$,!"%$$!($ ,((

!""#$ !" #

%"

&'()&('))*

'"($"%$-'( *$$.%("($"(($+

, - .

"/ " "

"

/

)"%"*$('$% , $ , 0" "

0

("( *$"+"!/"'!( "%0121323413/

,

1

,

$ -

.

, " " 223 ,

) %%"# "( $$!(!$+3%-4$5"2$35$5%"/5-/"6./--$%5%

$ &$!"!/$"'!(

!

6



"+

3#

.##%$)"/$ !$7 2/-+/..% 8" 3$+$% " $4/$ . .9/ %/52% 4/./-2%5$5. 8 $5/- /5%-5 9/$+.9')&&:&);&"&A*&>@7 .2$.% +" $5.5% " $-5/$+/ 8" 2/-+/- /" 2++ 8" -%% " %+/.-% " %5/% " ./--$%5% 6O.

P / '))E:A);'?@@>7 ./--$%5% 6 $ NN

$%'))E:>';&



"5

*55

!"#$%**'$"#%%$

) *$!"'!(

#$(($+$,!"%$$!($ ,(( "

0 ; $-/S"

=4/S" Y N NNN"

Z4 [

/SD5

( D5L/2

0

D5/-3D"

0

0

#-

8

'"($"%$-'( *$$.%("($"(($-"

)"%"*$('$$

("( *$"+"!/"'!( "%0121323413+ 41/."

5

')&' !-" $+" -/$+ #

/ !-./"%-%#

D5/-3D ! >)*A#

$ %

- !%$-#

" J

D5L/2" ( D5/-3D

/0 , 2 %$- -"

$ %

$

" - % ,

- " 0 2

" 2

5

) %%"# "( $$!(!$3$+$%"2$35$5%"82/-+/..%"+-%9%$-4%"6./--$%5%

8



) %%"# "( $(!$-"/8

$ &$!"!/$"'!(

-"$%$

.##%$)"/$ !$7\2%-$6/++% 4

%"

$-/S/&@@@:'A;A>E*@7\C$1%5/5 ." .%CC$5/5 L" /4/-/5 4 G /1/2'))):*;'&A'A7\$S/+5 " 6$+61 L2" 9/5 3" 4$% 4" 455$D $" 4+%..+/ -" 41-$5 62" /3%+2$5 4" /./%5 "3+42$5 +" 3-$54L/$5 " 9$5/5 /" 9/+.5/ " 9188 L" %58$5./ " L$65 28" L9% .C" +$41 L"+$54-%3$5 L" +// -" +C=4 $9" 2$3-/3- 3" 2/+5%C -" 2/%53 C" 5//4+/2$5 9" B588 4"-$$5/% 6" -%9./- /4" $ L" 916/-. 4" 1B1C% 4" ./%./+6$12 4" ./2+/ 5L" ./--$%5% 6".925 $" .%C5/- L" .2$.% +" 1.5 $" =9D$.. -2" =%32-/ 4" =%+5 ." =%53 6" 9$-/ $-;-K.GK K%L/9 '))A:@;A?E@: KA?@@)7\2/-+/..% 8" 2%-$6/++% 4 % % $ /G %; 3 9" $ $" 6 $" +K /" C" 2" -]N +!#/;531%"3'))>"&A>&>:&*;'?*@>7\2%-$6/++% 4" C$1%5/5 . G %K; $-/S %L/9 '))*:&&;*AEA7\C$1%5/5 ." %5/5. -" +%1CC5/5 ." 3-B/6DC 2" C$1%5/5 $" =/++%53 %" $-/B/ " 6+$C 5"692$558" $2/+ 8" .$ 2" /+%3$5 3" 3/-/5 -" C%C/2/5% $" C-291. 9" 2%31/+ "2%-$6/++% 4" 25/$5D -" /9 6" +$. 5" 9+15/5 " 91+B/ L" 55.$3 -" /-13.-$/./ "4/ %/5./ 2$" =+8 L" B%22/-2$55 2" 913$8/+1-%$%5/5 C" $+$%5/5 C G

N /1$9K'))E:*);*>@E&7\2%+%3% +" .$5.%5% $" 6/5/51.% $" C-%/6/+ 4" 6+/L$C " .12%5 -" -$2$BB..% " -4/++$ ".$35$- /" -%35$5% " $2$4-% 4" 2-$6/++% 4" 22$5% +" 6/++/..% %" .-9/+ +" -2/ +"2%/+% 3" .BB% 3$" 2/54% %" %5/% G F K /K'))E:&



5 5

5 65

!"#$%*%,$ *"!

) *$!"'!(

#$(($+$,!"%$$!($ ,(( -/2/$ 5

'))'

"

6 "

.

3 .$ " "

a

% 3 . $ " "

" " "

%3.$ ;

-

! # "I+

-I " 'A '))*" I$ I

- $."

'))>'))* '))*'))E

'))E

-" Z %28.

.[

+

-"

'))



'))*7\3%-4$5 +" /5-/ " $" 9$--%/- +" 4/+%$ " 4% ./8$5 8" 2+%5$- -" %%5/++% " /35$55 - $ + 8 - $. `b&."'))E7\9$--%/- +" %%5/++% " $" 4% ./8$5 8" 4/+%$ " 2+%5$- -" /5-/ " 3%-4$5 +" /35$55 %

;

1 / %/'))E:A);AEE@7\2+%5$- -" 4/+%$ " 3%-4$5 +" /5-/ " 9$--%/- +" $" 4% ./8$5 8" %%5/++% " /35$55 ;

/

"A)"'"')) (" *)(+ # % *,

A)c ; 0

!"#

"+ ,

0% 5 . 2 ! 8 6#

0% / 2

* !#.

'"($"%$-'( *$$.%("($"(($

4

!963#

$

% !%38%#

+0%

: "

"

963

0%38% !%386& '#" d

0%38% "

$

"

a ; " " "94+3 4%$5$ 0%"

2 " " 0%

0%38%

1

0

%" 0

+ =%5 "

'>c

*

F

!F#+

4%$5$ * 0

-"

$%%;

13



\.)">(\%*)(+\2!A#;\3&))(\.&*)(\94+e*)(\3?*\&A)(?*9$,/-

0+a*;



426

4/8 /BB$5$$$-

$ &$!"!/$"'!( %

!#

"%% 0 !% ."="

" #

!%.2#+ !$ % .# "

/0

0

.##%$)"/$ !$$

6%6+%3-$8%$4%-%8/-%2/5.;& \/ $9 / F NL5%'))E:@?;&>)E&*' \CF - G N F N /%5!/%#L5%'))*:@;E)E&EE \2 $ / " " FNL5%'))>:@E;&?*EE*;>>?*>@ \+ 4L" 4F -6 -

" N " KL6 26'))':?);&:&&&;:&A;&)@@&)*AA 2. $ / G N; &' -'))>:E>;'@'A?A> / C / K

K F K;L$2$'))>:'@';&>>)EA* + $2" F 2 F N

K /-

'))E:&A;';&EE'& F /6 O/G N N PF&@@':A?;*@'@>' = 8 $ K K N /L&@@A:';'AA?>A L $ K

; =09 K/+!=9/+#K.'))':'A;



($+$

5 55

($+$

5 5 55

!"#$%*!,!"!

) *$!"'!( ;4+3%-4$5

#$(($+$,!"%$$!($ ,((

,

!" #

3;

:

: ,

! (8 #

*) *>

"

*?

+

a

'"($"%$-'( *$$.%("($"(($ &')) !E))

E))

#$ ,

" .%%%

> ; 3 $ 8"34"3$84"3

. !

#

, a a

%;

34; %

. ( % " ,

%E?&'&>

3$; %

. ( """%E?&'&>

18



34f$8;%

$ !

# ,

!

" #

!"

" # ! .%%#

""

)"%"*$('$

N

%"

a

!#a

("( *$"+"!/"'!( "%0121323413+

')&) " ')&'" , " E

E)A *? !AE@ 'A> #

g

N

,

N

%

, &



.%%

3%2 ')&) 6*E')&):'# + ;

!.%%#"

3%2')&&"&'&A')&&:A# -. K

')&& $%- $- 8" 5" K $K = " 4 !1$#" A>')&&># -. K

/ K - "'"+!

#"?@')&&:*# .%% -. K

Y

K %

5NF" 6 2

" KK !$#"'A'*')&':E# . .%% F ;

N K

h K %

5NF" 6 2

" KK!$#"'A'*')&':')&'

20



$

696

!"#$%*%,$ *"!

) *$!"'!( -

0$-99

#$(($+$,!"%$$!($ ,(( 8 K

(

-

'"($"%$-'( *$$.%("($"(($-

Z-

[

- !'))E# Z [2

'))?% E

+ "

Z-

[ 7\$

;

7\4 / !"$"+%+."8"i#7\

7\

7\

(" "

)"%"*$('$8&

')&'

8'Y%

')&'')&A

8AY')&A

8>$')&A

("( *$"+"!/"'!( "%0121323413+ E $ 4 , /0

!A&')&A#

) %%"# "( $$!(!$$"%%5/++%

21



$ &$!"!/$"'!( 8>))))

-

0$

.##%$)"/$ !$ ;((NNN(G HjklNjlj>*)l%j&A&

22

Registro Tumori


$

)

!"#$%*/"!(($

) *$!"'!(

#$(($+$,!"%$$!($ ,((

')&&

'"($"%$-'( *$$.%("($"(($+

. +

+;$#

.

;

-

6#

4 #

4K94#

/#

8$-8#$ %

N

%

- . +

%2@"%2&)

%2"&b'bAb

. F

+

"

"

. a

; " "

"

%"

"

% " "

"

3

- . " " - $%4 0% $%4

%

%$- Z% % 8 [ Z/%2[ Z$/["

%$-:

$ % -.

23

Registro Tumori


)"%"*$('$+

.,

("( *$"+"!/"'!( "%0121323413/

')&) % N

$%-.12/%2

) %%"# "( $$!(!$61"83%+$-4%"$.-%$-$"--$54%"-

$ &$!"!/$"'!( ` 3

! (.14%21+.%/5.-%%

.##%$)"/$ !$3 NNN .

" " N

%-.%NNN

7 8/-+$D L" ./+%$-$819/- /" +-./..%/1+/5. L" - " /6/-39 L=" 26/- 9" 8-2$5 4"6-$D 8 K /; >) ')&' / L ')&A:>@;&A>)A7 5/+916/- " B$$ 2" /6/-39 L=" -$%.% /" -$9.$5 L" 9++/B/C 6" - " $$-/+/%4 ."6-/55/- 9" 354 $: /15%/ 1-%$+ =-C%53 3-1 " K / 1 $ ; $')&':'A;&A'*A>7 +%/ 2" 8-$5/9% " 61BB5% " B$265 " 8$+%5% 8" -/..% /" /--$%5 4" %$9/..$ 8" B$5/..%-" /-/++% 2" 8/--/..% " +$ -$ 8" 45$. $" 4/ +%% " 2$535/ +" 61 " .$3+%$61/ 3" 614-5%2" 6%$5.% +" 81 2" +%2%5$ -2" .12%5 -" %88/- " 2$4/441 $" 6/++m 8" 3%$2%5 $" $54/+$ 3"$51++% 2+" 4$+ 2$ +: $%-.12 =-C%53 3-1 N

&@@&'))*%K; K. K')&':'';'7 / . & 4 / : $ 1 3 6 . 1 .:

2" 3" +" 4 4" 3 " 3 2" 2 8" / / . ' 4 -. : $ 1 3 6 .: $" - 3" - " 5" " B - 1

1: $+ .&':2 / 41 / .: 4 2 : 1

: $ 1 2

5: 6 %" 2 -. " 6

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m 8" 81 2" 2$4/441 $" %.$-/++% " ./$54-% -".12%5 -" 1+%3% 6" 8-$5/9% : $5/- $54 $%4 -/3%.-%/ +%5C$3/ !$-+# .14D FN $%4%K 9$$-.6L'))@:&));?>);?*?E*7 1+%.% 4" 2%%5/% 3" ++%5$ 5" 4/ +%% " 8/4/-% 2" 8/--/..% " 8%5$-/++% $" 8$ 8" 2$535/ +"5$+45% " /.-/++$ 2" 5.% $" /35$5 5" %35$ $" B$-5/ 2" B-B% 2" B$$ 2" $% /: %2$.=-C%53 3-1 /

; K K

25

Registro Tumori


6L'))?:@@;>'A)"/5-%$-"+K"'))&

26

Registro Tumori


55 9- - 5

5 9- -

Registro Tumori


%2$..;/"8

/15%/;963"- 9

$ &$!"!/$"'!( `

- 3

.##%$)"/$ !$+ NNN

NNN7 /-9//5 -9" L$5/59/%L5/5 2+" $12 C1" B$5/..% -" $+4$-/++$ $" 9++/B/C 6" 6-/=./- 49"9$C1+%5/5 ." 9-/56+$ " 6-/55/- 9" 354 $: /15%/ 1-%$+ =-C%53 3-1 / 1 $; 5 &@@) /L')&A:>@;&>&>'&7 /-9//5 -9" 354 $" L$5/59/%L5/5 2+" $12 C1" 6-/=./- 49" 9++/B/C 6" -/..% /"- " 9$C1+%5/5 ." $$-/+/%4 ." 6-/55/- 9: /15%/ 1-%$+ =-C%53 3-1 . / 1$;

$')&A:'>;*)?&A;&)&)@A7 -%6/- 4" $2%$5 2" + ./-%/-/ -" - " 8/--/- $" $1..% +$ G N $')&&:'*>; && / ;

N 1/L')&)4:>E!&?#;AA*&&: K&?>'7\$5 4/ 9$5 $" 354 $" $5 -5/5 4L" -$9.$5 L" 9++/B/C 6" B$5/..% -" /6/-39 L="L$5/59/%L5/5 2+" 6-/55/- 9 %

" 9F0 K / 1 &@@) '))> L ')&& L&):'@!'#;&@'@/')&)5'@7\B%35 3" 6/--%5 8" 3$..$ 3" Q59/B 2L" $5 4%LC 6" $5 /DC/5 /" 8-$5%% : /1-$-/ =-C%533-1 F / &@@*&@@@; K$')&&L:''!&E*7\$3$5 /" 8%+%%5% " 4% 15B 4" -188%5% /" B$5/..% -" - " 6/-./.. " 2/-+/..% 8" %5/38

/')&)$:A>!>#;>?A@7\+/$3/ " %+$++ +" 4/ $53/+% -" 61%/- $2" 8$%-/ L" 3$..$ 3: /1-$-/ NF / % L ')&) L&*:&'E!&'#;'@'?A>7\354 $" 9++/B/C 6" L$5/59/%L5/5 2" 6-/=./- 49" 6-$D 8" - " 9$C1+%5/5 ." 6-/55/-9: /15%/ 1-%$+ =-C%53 3-1 2

]

; % L '))@ 4 &:&'*!&'EEE /; "K K/L'))@:>*;@)@A)7\8-$5%% " $$%$ -" 3-$54/ /" $5.$`1%+$5% 2" %25/..% $" $++/2$5% " 3$..$ 3" $5. 2"B%35 3" 6-$D 8" L$5/59/%L5/5 2: /1-$-/ =-C%53 3-1 !3%$2%5 $" 2$35$5% " $.-/ 3"$.-%$-$ " - " B$5/..% -# . ; / / L '))@: >*;&)E;

K&'/L'))?:>>;&>EA'7\%-3%+% 3" 3$..$ 3" %+$++ +" $$%$ -" 6%33/-% $" -/..% /" +1.B L2" $% /: /1-$-/=-C%533-1N

/$ '))?:&'E;&>&A?7\6/--%5 8" 4/ $53/+% -" $5. 2" - " 6%/+C$+$.$ 2" /6/-39 L=" $5.$`1%+$5% 2:/1-$-/ =-C%53 3-1 ]

/ &@@*@@; /1-$-/>K+'))

Registro Tumori


55

)5

!"#$%*/"!(($

#$(($+$,!"%$$!($ ,(( $

%.$. ! #

- -3;8

N/

-

'"($"%$-'( *$$.%("($"(($+ , $+

. , "

% - . + -%%;

:

. .:

: .5

'))@,

N=%2

)"%"*$('$+ ,

&@?* , 5

/ &b

:

-

1.%+%BB%+ " " ,

N G" $

" ,

` %.$." " p

4

%4 &) "

%.$. p

,

'))>'))* " "

+ " - . " , , " '))?"

("( *$"+"!/"'!( "%0121323413/

')&'

-3-$22$')&'$

0

30

Registro Tumori


) %%"# "( $$!(!$$3%$2%5"$.-%$-$"--$54%"-

) %%"# "( $(!$+

$ &$!"!/$"'!( +,

.##%$)"/$ !$3NNN

7 8/-+$D L" ./+%$-$819/- /" +-./..%/1+/5. L" - " /6/-39 L=" 26/- 9" 8-2$5 4"6-$D 8 K /; >) ')&' / L ')&A:>@;&A>)A7 5/+916/- " B$$ 2" /6/-39 L=" -$%.% /" -$9.$5 L" 9++/B/C 6" - " $$-/+/%4 ."6-/55/- 9" 354 $: /15%/ 1-%$+ =-C%53 3-1 " K / 1 $ ; $')&':'A;&A'*A>7 /35$5 5" - " 5.% $ % K N

H5 L5%')&':&)>;&)>)&7 $$%$ -" 2$-.%5$ +" %539/+2$55 -" -/..% /" 4/ +%% " 8$+%5% 8" 31BB%5$.% " - ".$3+%$61/ 3" .12%5 -" /-/++% 2" B$5/..% -" 4/ $53/+% - $ K N

K ; %K % L '))@: &'>;&'))*

31

Registro Tumori


&9 $)9( -

($)9

!"#$%*/"!(($

) *$!"'!(

#$(($+$,!"%$$!($ ,(( % !

#

/% ,

- . ,

% /%!/

#

'"($"%$-'( *$$.%("($"(($& II

' !#

:"A % "

-.:"> %

-.* % >"

4

E+

)"%"*$('$+F

("( *$"+"!/"'!( "%0121323413/

NF

) %%"# "( $$!(!$+8%-%5%"-"$/-4./"%5/%

$ &$!"!/$"'!( %,

! (.14% 21+.%/5.-%% + ,

/%

55/%5%;$//

.##%$)"/$ !$ 5 4" $" 5

C-" C" - 5

" .]q

$" 6 $" 3r $"5 " - +" . -" CK ." + L" CF -" " 6 8" - "2

$" -" 62 96" 6 3" 2] L" BF " 9

3" 2 6"6 " C N C." 6 22" 6 9" . $" 2 3" . -" + /" 5" 8" 6 " " - / F K ; K!/%#/2')&&:E?;

Registro Tumori


5($

)5

!"#$%*)")* (

#$(($+$,!"%$$!($ ,((

%;&

'$

A

>

*

$

"

'"($"%$-'( *$$.%("($"(($% ) &>

+

+ K

5

'))@ ,

" " ,

! #

%

2 "

)"%"*$('$$$ ')&& u

'))?'))@

N,')&)

" ! ')&)')& ')&A

("( *$"+"!/"'!( "%0121323413+5

')&& ,

'))?'))@

N u')&)

%

%

-.% ! #

+ ! # a % -.%

'))< $%-.12 ') $%-.12

!)&> #" !&*&@#!')'@#% $%-." /1-$-/" /+% $% ! %$-#

34

Registro Tumori


. %

5

'))E ,

5

')&' , %"

6 4

$ % - . !$%-.# % ,

')&A !% % - ')&' % /l')&A:A

7 6 3" 3" 3" 3" 3" 4

" 2 + K; $ % K -2

Registro Tumori


7 3" 4 3+" 6 3" 4 /" % $" 3" 8 $: .-/ 3 / N %K; .-/ ] : 4/K6"$%/6'))@:*A;&*'*

7 3 3" B 3" -" L=" 4 /" C " 3" 6 -"

$:/1-$-/ =F 3 / K N &@@*'))'/L'))@:>*;@@'&))*

7 4$2$ /" 2$1+/ 22" 2 2+" $+/% 4" 39%+/5% 2" %/..$ /" %$5% " 2$35$5% " $.-/ 3"2/-+/..% 8 + ; K " %K / L '))@ A O/ P22%4;&@

7 2$1+/ 22" %BB%5% +" B/5/ C" $C-/ " -%9%$-4% + 9N F F N" &@E)'))>/ 9 '))@: &&*;@@'&))*/'))@8'&22%4;&@'A&&E)

7 6-/55/- 9" 8-$5%% " 4/ $53/+% -" 2$-3-$3/-$ -" /-4/9%$ $" 3$..$ 3" $++/2$5% "%+$++ +" +/2$5 2" $5. 2: /1-$-/ =-C%53 3-1 + G /')))'))'/L'))@:>*;&)'?>&/'))?4&E22%4;&@)@&*>@

7 8/--$-% $" 4$2$ /" /%5 $" -54/++% -" $1% " +$./++% 8" 8/--$-% " 2$$-%5 2" 2/-+/..%8" 2$/-$ 3" $-%v 2" $.-/ 3 $ N %K; K

K $%/ / L '))@: >*; A'?A> / '))@ L ? 22%4;&@&A*A*?

7 4$2$ /" -54/++% -" 4/ -$ 2" $-%v 2" $-+% 2" 6/++$5% 88" 2$35$5% " 2/-+/..% 8" $.-/ 3"/%5 $: %.$+%$5 $%$.%5 8 /4%$.-% 9/2$.+3D $54 5+3D !$%/# %K; $ K % $ 9K K !$%/# / L '))?: >>; '&)&* /'))?$')22%4;&?@&

7 4$2$ /" $.-/ 3" 2 2+" 2$1+/ 22" B1+ +" 2$35$5% " 2/-+/..% 8 . ; -K !%K#/L'))E:&E*;'>)@

7 C$$.9 " ./+%$-$819/- /" -/..% /" 2$35$5% " %S " B$265 . / !&@

Registro Tumori


7 %2% " $.-/ 3" 2 2+" ./--$%5% 6" 2$45 /" 2$35$5% " 2/-+/..% 8 &@

Registro Tumori


$571:91=8

)71:91=8

!"#$%*)")* (

) *$!"'!(

#$(($+$,!"%$$!($ ,(( % ,

" ,

"

` , a a

%

-

&@

% ,

+0 , !&*&@#

'"($"%$-'( *$$.%("($"(($% - . %"

" ,

""

+ ,

!4#

" &*&@ "

!%4@;&>)')?#"

"

" !%4@;''*'A@#+

, 1 %

$%/+%5///-$.%/4/++$-%+/$B%5/& / &@

-:'

"

"-..

$%/A ,

)"%"*$('$$ ')&& ,

'))?'))@

N,')&)

" !')&)')&')&A

("( *$"+"!/"'!( "%01213234135

')&& $%-.12

/u

N % ,

! &@E*'))

) %%"# "( $$!(!$4

$+/%" 8 +$BB$-$." 2$/-$.$" 2$35$5%" 2 2$1+/" 82/-+/..%"2+2"6./--$%5%

$ &$!"!/$"'!( -"-

.##%$)"/$ !$7 $%-.12$%/ =F 3 % % - ')&' % /l')&A:A*; A'?A> / '))@ L ? 22%4;&@&A*A*?

41

Registro Tumori


; 5

*5- 5 5

!"#$%*

) *$!"'!(

#$(($+$,!"%$$!($ ,((

"

NN

/.'

'"($"%$-'( *$$.%("($"(($.

5

"

N

N

0 %

)"%"*$('$\\4\8\%

("( *$"+"!/"'!( "%01213234135

')&),; N

!#: N

:

N0

:

K5

')&&

')&',0

) %%"# "( $$!(!$23%-.."$-.$+/

$ &$!"!/$"'!( `,

0

42

Registro Tumori


>5

? @ 5 5

!"#$%*)")* (

) *$!"'!(

#$(($+$,!"%$$!($ ,(( 8

0

&@b + , A %- . %

!-.%# &@E*

1

"

" a

" 0

'"($"%$-'( *$$.%("($"(($

; ( " " 0

&&))

&@@@" *

&*b+0

, "

% ,

&@@E

)"%"*$('$$

("( *$"+"!/"'!( "%01213234135

'))* ,

Registro Tumori


; % $%/ . K -K 9 ')&&: @E; >*&;&)AA'>( ')&))AE&'@

7 4$2$ /" 2$1+/ 22" 2 2+" $+/% 4" 39%+/5% 2" %/..$ /" %$5% " 2$35$5% " $.-/ 3"2/-+/..% 8 + ; K " %K / L '))@: &?; >'*A) ;&)&)@@

Registro Tumori


$ 5 @

) 5 ( @ A

!"#$%*/"!(($

#$(($+$,!"%$$!($ ,((

! ""#

'"($"%$-'( *$$.%("($"(($%;&

" :' ;

:A

!

/"

5$#:>

:* "

+;

::

!#:

8;;: ; - . " $

4 "$ -

$"$ -

2: ; - .

!3#

("( *$"+"!/"'!( "%0121323413+

Z%

% .["

8

-

) %%"# "( $$!(!$61"+3%-4$5"$.-%$-$"-"%6-$.

) %%"# "( $(!$+22$.

$ &$!"!/$"'!( -

-.&8

'))E'8

'))?

46

Registro Tumori


.##%$)"/$ !$7 6-$. %-/5/" $.-%$-$ %+%$" - ./8$5" -5 313+%/+2" +$-$. -%.%5$ / B$5/..%-6/-. $

.;

H

S%%-

0$%-.12"6')'&''')&A7 B$5/..% -" .$B% 2$" - 5N

5 $ / L ')&):>E;>E'E7

S%%%-

0$%-.12"E;'AE

47

Registro Tumori


5.!$)78

.!$)B78

!"#$%*

) *$!"'!(

9 6 $ C / $ 4 C 6 ')4E@&&*9

#$(($+$,!"%$$!($ ,((

Z [

'"($"%$-'( *$$.%("($"(($%

&@?)'))>"

N '))> ; " +" /" " / " " 3" 8" 5""..+ Z [" "

Z [ a

"

" "

%

" "

5/

a

/

%,00

N!'))

Registro Tumori


$55

55

!"#$%*/"!(($

#$(($+$,!"%$$!($ ,(( %

- .

"

"

p

'"($"%$-'( *$$.%("($"(($+

"

"

. a

"""%"

"

"

%5%%%%

- . " "

F " "

%

% d "

"

Z%2$..[

$%-.

)"%"*$('$-3-$22$4%$..%%.$')&A.')&)

("( *$"+"!/"'!( "%0121323413

;&@@?'))?

;&@?*'))@2

;&@??'))@

) %%"# "( $$!(!$61"83%+$-4%"$.-%$-$"--$54%"-

$ &$!"!/$"'!( .14%21+.%/5.-%%%2$..2

!/"8#%2$..!4"-$"5#

.##%$)"/$ !$7 $-BB% 8" 3%++%. $" 58-.%5% 2" 4/+ 2%.- $" $5% " 4/ 2$- +" 3%-+$54 " - "5$+45% " 4$++$ $+2$ " B-B% 2" 3%-3%-% " /35$5 5" 1B%C L" -5 3: 5. =-C%533-1 -F

N 9 N

&E%5C>$ ; K K 5.

+')&A:&>;&E?@*>;?*?E*7 1+%.% 4" 2%%5/% 3" ++%5$ 5" 4/ +%% " 8/4/-% 2" 8/--/..% " 8%5$-/++% $" 8$ 8" 2$535/ +"5$+45% " /.-/++$ 2" 5.% $" /35$5 5" %35$ $" B$-5/ 2" B-B% 2" B$$ 2" $% /: %2$.=-C%53 3-1 /

; K K6L'))?:@@;'A

Registro Tumori


5. ) .7.-C&65"8

. 5 A

!"#$%*/"!(($

) *$!"'!(

L== " !# =F F +; 9 "!4#"9!%#"-B!%#"L4

!#"$ $!8#

#$(($+$,!"%$$!($ ,(( % "

/ 5NF -" "

-.

1/% !" # /"

//-%

'"($"%$-'( *$$.%("($"(($% " N" &* % " &A / !

=+ " 6

" -" /" $"%"1C#

%,&)=FF;&!#'

A">""*%

E%@;&''

8/-+$D L" ./+%$-$819/- /" +-./..%/1+/5. L" - " /6/-39 L=" 26/- 9" 8-2$5 4"6-$D 8 K /; / >) ')&' / L ')&A:>@;&A>)A

NNN

53

Registro Tumori


$#+

)#+

!"#$%*",$") '$!

) *$!"'!(

#$(($+$,!"%$$!($ ,(( -

6

/

'"($"%$-'( *$$.%("($"(($+

!" " " #

6

+

6

, "

, "

')))c 6

" **c

#" G" , 0 :

"

5

0 `

% "

N

%4A : d

%$-$%-.12% " "

"

"

"

%

$+"

" " "

-"

4 !#" %

%$- Z% % 8 [ :

6

$ % - .

54

Registro Tumori


"

F "

)"%"*$('$+

6

, "

, "

'))

Registro Tumori


, 6

0

0 N

" '))

Registro Tumori


;-

$-

!"#$%*

) *$!"'!(

#$(($+$,!"%$$!($ ,(( +

0

% "

0 "

0"

$+ ( (

"

'"($"%$-'( *$$.%("($"(($+

% + 0

( .

o0 0

%

0

% ,

0

0

4

%

N

,

-.d0

G

0

)"%"*$('$5

'))@ ,

N

'))'

'))>

0

! *))?#

5

')&),

0

5

')&& " ')&' $+

% : ,

("( *$"+"!/"'!( "%01213234135

')&A ')&>

"

%"

! "

#

58

Registro Tumori


) %%"# "( $$!(!$--$54%"+$9/.."5/35$5"-B$5/..%

$ &$!"!/$"'!( %,

.##%$)"/$ !$ / . & 4 / : $ 1 3 6 . 1 .:

2" 3" +" 4 4" 3 " 3 2" 2 8" / / . ' 4 -. : $ 1 3 6 .: $" - 3" - " 5" " B - 1

1: $+ .&':2 / 41 / .: 4 2 : 1

: $ 1 2

5: 6 %" 2 -. " 6

: ( /: $+ 6%: 3 $ % "-')&&2')&&

59

Registro Tumori


) (!' 5- +$$ 344=

(!' 5 - +$$ 344= $

!"#$%*/"!(($

) *$!"'!( %/25./

#$(($+$,!"%$$!($ ,(( +1 % !1%# '))@ %%

.52 `

"

$

" , % " : Z[

'"($"%$-'( *$$.%("($"(($+

,

)"%"*$('$+

,

'))@

')&) 5

')&) ,

"

5

')&A ,

0%%%

("( *$"+"!/"'!( "%0121323413+0 % p /0

0%%%

) %%"# "( $$!(!$$.-%$-$

) %%"# "( $(!$48$

.##%$)"/$ !$7 1% 1 % ; .52 . 2"

'))@ +" 3N 2" =F " $ - B "-

/7 8 " " $" B - .52 " %% 5

/')&):A>;&'*?7 " 8 " $" B - +

.52 ;

H

S%

$%-.12"'A')&)

60

Registro Tumori


)& D &9 5 7491=8

) ) " ) ) &9

!"#$%*)")* (

) *$!"'!(

#$(($+$,!"%$$!($ ,(( + , : &

Registro Tumori


& F K

' F - . ! '))

A F 4

&@@E!

4#

5

')&A

;

&- 4

' - $%/

("( *$"+"!/"'!( "%0121323413+,

')&&

/u ,

N '))@"@)c

/u0

5

')&A , ! #

0

) %%"# "( $$!(!$4

$+/%" / 6-%35$-4/++" 8 +$BB$-$." 2$/-$.$" 2 2$1+/"82/-+/..%"2+2"3$.-/"6./--$%5%"-B$5/..%

) %%"# "( $(!$$%-.12$%-.

$ &$!"!/$"'!( -"-"1/8

Registro Tumori


.

" ?&@EA'>?

+

-. " "

&E)))(

0A))))

)"%"*$('$5

')&& ,

` , ."

! G . #5

')&' ,

0 , N

! #"F

.

')&A

'))

Prevenzione secondaria


43- 5.8Y`-7 +$5./ - -5 3 %

K 5

5.8Y`-7 313+%/+2 -5" $2/+$ 3%16%+$." $-+ 5$+45%" 2$51/+ B-B%" /2$51/+$ $539%55%" $1--$$+%%" $+ 4$++$ $+2$" +-% B$5%/-" $5.5% 8/4/-%%" +$14% $53/+5%" ./8$5%$ -$54%5%"- 2$3+%/..$" /..-/ 2$5%5%" -/5$. %BB1.%" $55$ %$" 5/-/ /35$5" 2$- B$$+%/++ 4% $..%$B%5/ / %54%$.-% 4% -/ 4/% -3-$22% -3$5%BB$.% 4% -//5%53 4/%.12-% 4/+ ++ 4/++1./- %5 %.$+%$ 5 . 8 Y`-7 4$5%/+$ 3%-3%" +%%$ 3%-4$5" +/5$-4 /5.1-$" $+85 8-%3/-%" /13/5% $%" 2$-B$$ + -//5%53 2$223-$8% %5 %.$+%$; 1-/D '))>/ 4$.% -/+%2%5$-% '))* 5.8Y`-7 -/5B$ +$5./" $2/+$ 3%16%+$." 313+%/+2 -5 % 4$.% 4/++$ 1-/D 5$B%5$+/ 1++$`1$+%.W 4/+ 'b +%/++ -//5%53 /- %+ /-%$-%52$ Y 455/ %5%.$./ 5/+ '))>/-$.-%5$B%5$+//-+$-//5B%5/4/%.12-%8/22%5%+%Y`1%5.-$-.7 -5 3" 3%16%+$. " 5$+45% " B-B% 2" $539%55% /" $+%% $" 4$++$ $+2$ " B$5%/- +" 6$-$$" $53/+5% " -$54%5% " 2$3+%/..$ -" 2$5%5% /" %BB1.% -" %$ $" /35$5 5" B$$ 2 +

% 5.8Y-7 5.% $ /35$5 5" B$$ 2 % 4 =

; 5.8Y-7 4$5%/+$ 3%-3%" +%%$ 3%-4$5" +/5$-4 /5.1-$" $+85 8-%3/-%" /13/5% $%" 2$-B$$ + -//5%53 2$223-$8% %5 %.$+%$; 1-/D '))* / 4$.% -/+%2%5$-% '))E 5.8Y-7 -/5B$ +$5./" $2/+$ 3%16%+$." 313+%/+2 -5 `

;

K

5 .8Y-7 313+%/+2 -5" $2/+$ 3%16%+$." $-+ 5$+45%" 2$51/+ B-B%" /2$51/+$ $539%55%" $1--$$+%%" $+ 4$++$ $+2$" +-% B$5%/-" $+/$54-$ 6$-$" +$14% $53/+5%" 2$-%$ 45$.$3$%2" - 2$3+%/..$" /..-/ 2$5%5%" -/5$. %BB1.%" $55$ %$" 5/-/ /35$5" 2$- B$$+

0%5.8Y-7 -/5B$ +$5./" $2/+$ 3%16%+$." 313+%/+2 -5 `0

;

K

5 .8Y-7 4$5%/+$ 3%-3%" +%%$ 3%-4$5" +/5$-4 /5.1-$" $+85 8-%3/-%" /13/5% $%" 2$-B$$ +

%; K '))< 5 .8Y-7 +%%$ 3%-4$5" 4$5%/+$ 3%-3%" +/5$-4 /5.1-$" $+/-%$ ./8$5%5%" $-+ /5-/" -6/-.$

66



$.$35" $+$ %%5%" /13/5% $%" 5/-/ /35$5 .

%; &@@?'))< 5 .8Y-7 - 3" 3 " 5 " B 2" $ /" $" 4

" B +" 8 $" $

" " 2 -" 2 /" -" % $" 5" B 2 /G

%K / '))


Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in PiemonteScheda: 3.001 bis

5 5 - 5 & 5 5 341393410

#9 5 5 ( 5 5 55341393410

!"#$%*%,$ *"!

) *$!"'!(

#$(($+$,!"%$$!($ ,(( `

"

-

'"($"%$-'( *$$.%("($"(($% "

" " + ,

%

+ "

"

" a

d

+ ,

$

NF "

" "

%

" "

)"%"*$('$%

')&A,

("( *$"+"!/"'!( "%0121323413-//5%534/++$2$22/++$"4/+++4/++1./-/4/++55

!')&'#" , ;

-%$33%-5$2/5./($-854%2/5.!EE'#

-!&EE#

0

1

.!A# N

!`.2#!&@# N

!`.2#!A*#

68


Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in PiemonteScheda: 3.001 bis

%

;H!??# 4

!*@# $+%2/5.$B%5/ /4 $..%%.$0 8%%$ 5.- +/ 2$+$..%/ 4/+ 6/5//-/ p -

0$

H !&@A)7 -5 3" B$$ 2" 5$+45% " %$ $" 6/--%5 8" $539%55% /" 4$++$ $+2$ " 2$33%5 ."/..-$BB% 2" /35$5 5 3% %

0 / &@@@: 'A!?)#;&A'7 $5 6$++/3%L/5 2" $5 4/5 $CC/-$ 2$-+/ /" $.5%C L" +D53/ /" $-6D5 2" $5..%+$ $" -5 3"9$66/2$ 4L8 N

/ 1 !/1#" / L '))):AE;'&&7 -5 3" %+1..% " $.-%$-$ " 25.$5$-% 3" 39%-%539/++ 6" +$5./ -" 3%-4$5 +" B$5/..% -"

72



2$5%5% /" /35$5 5 .

=F 3 %

." %K; K

K &@@'@? 6 L'))*:@A;A*;'E?*



-

0

" -'))>7 -5 3" 3%16%+$. " 5$+45% " B-B% 2" $539%55% /" $+%% $" 4$++$ $+2$ " B$5%/- +" 8/4/-%%$" $53/+5% " -$54%5% " 2$3+%/..$ -" 2$5%5% /" %$ $" /35$5 5" B$$ 2 +

% % Z 5

`[8"'))*7 -5 3" 3%16%+$. " 5$+45% " B-B% 2" $539%55% /" $+%% $" 4$++$ $+2$ " B$5%/- +" 8/4/-%%$" $53/+5% " -$54%5% " 2$3+%/..$ -" 2$5%5% /" %BB1.% -" %$ $" /35$5 5" B$$ 2 +

%%-

4

.2"B2/5

`2'))E7 -5 3" 3%16%+$. " 5$+45% " B-B% 2" $539%55% /" $+%% $" 4$++$ $+2$ " B$5%/- +" 6$-$ $"$53/+5% " -$54%5% " 2$3+%/..$ -" 2$5%5% /" %BB1.% -" %$ $" /35$5 5" B$$ 2 +

%%-

4

.2"B2/5

2'))



/ " " - -

!--#"4$8/0 0

0

.

) %%"# "( $$!(!$ $-2$-+%" - 6-45" $

$-%3+%" 4 $/++$" 3 %5/"4

4% 15B" $ 4% +/" $ 8-%3/-%" + 3%-4$5" / 2$5%5%" 2 2$5" $.-%$-$" %.$-/++$" -" 5 /35$5" /5-/"3,/$"2.2$.%"/-3%5%"-B$5/..%

$ &$!"!/$"'!( 8 / $

.

&@@'&@@?

!

# $ '))> - - -

2" %

." % 4

,4$8

! (.14%21+.%/5.-%%

;$ 8

.

Z[.%

%%

%

3%2

5NF/.!#,

.##%$)"/$ !$7 /35$5 5" 3%-4$5 +" 5.% $" -5 3" /5-/ %

02&@@@: /

76



/"/$"+G"'))E7 3%-4$5 +" 3%-3% 4" 8-%3/-% $" 6-$/..% " $% /" /.-/++$ 2" 5.% $" 4/0 6%$59% : 3-1%.$+%$5 /- + -//5%53 2$223-$8% %

/'))E:A);*@"&&>7 .x-56/-3 " C/2/.+% +" $15/ 5" 98%54 " $5..%+$ $" g-$41- 6" $% /" 31+4/58/+ "$B$/4 /" 8-%3/-% $" -4-%31/ " 5.% $ $ K G //L')&):&@;?



'55 @ 5

'559

!"#$%*" !($

) *$!"'!(

#$(($+$,!"%$$!($ ,(( \$

\ \

"

" "

'"($"%$-'( *$$.%("($"(($\4!>)#

+

3G\4 !`.2#\2 :

:

\8

F" "

\!"#

("( *$"+"!/"'!( "%01213234133 `.2 , " /0 A) 2 $ N `.2 ,

; '))

. &@@&@@ !@))#" ! ." 8 4 !%-+#&@@'@*; E))#" *) 3

2!3%2# &@@ ,

6 1

/12$ $ ,

')&)

/12$

/12$,

$%

'))> ,

"+

3/

5

'))A'))E , `.2

-

.5

'))E , `.2 N" - %

- $

N

8 5

')&) >) N ,

,4

) %%"# "( $$!(!$- 6-45" 4 $/++$" $ 4% +/" 2 2$5" %.$-/++$" 5

78



/35$5"/5-/"2.2$.%

$ &$!"!/$"'!( % /

/ &@@@ '))> 4 '))* '))?

/ ! 9 # 5NF Z/[ %

5 . 8+/12$

6 1 5

'))? , 2

1

- " 8 3

.##%$)"/$ !$7\5.% $" 4%.$5./ " 2$5 2" 6+$2/D -=" 44 2" 3%-3% 4" 3-/D ." +%5 4$" $%561-D L-"/35$5 5 $54 .9/ /$ -L/. =-C%53 3-1 2

/ $ I' / 6 I 6

'EA) ')))/L'))):AE!*#;&'A!bA@*#7\4%.$5./ " 2$5 2" 5.% $" $.$+%..% +" 8%+%%5% +" 3%-3% 4" +$BB$-/..% 23" 2$-9/% "/-8/..% /" /35$5 5 2

%K $ I'/ 6 I 6

'EA) '))) / L '))): AE!*#; &'A!bA@E#7\5.% $" /35$5 5" 6+$2/D -" 6-45 -" $.$+%..% +" 44 2" 4%.$5./ " 3%-3% 4" 3-/D ." +%5$" +%5 4$" 2$5 2" $%561-D - 4

.

4 % K 5"6 2" = " . " L" / 3

`K $ 2 K

" A / / " / $ "+G"'))&7\6+$2/D -" 6+%9/-..8. 2" $.$+%..% +" .$ $" 3-/ 2" 9++$54 -" C$182$55 2" /--D 5"5.% $" -/4254 C" $%561-D - !/12$ =-C%53 $-.D# . /L'))):AE;''??@A7\-1.3/- /L." 6$-./+%5C 9" 6+$2/D -" +%9/-..8. 2" $.$+%..% +" 81-`1/. $" 3-/ 2" 9++$54-" L$C/B -" L1+%/5 L" -1/5 5" 09%33%5 5" /./-/ L+" /.%. LD" 5.% $" $%561-D -" $5 4/ /+4/L9" !/12$ =-C%53 $-.D# `K + . 6 / L '))&:A>"E)



; '))A %; -

. 2" B 2" " 5 ` + % + ." -" '))*" ?>@/'))#

74

00

0

'"($"%$-'( *$$.%("($"(($7

0

;7-""

:7'#(

':7A#!*#:7># ":7*#

:7E#-!'%#7 -

%

%

7 4 ; &@')) : &&>)

E)



/

- .& %

-

/0 0

N &) 0 ,')&&/0 0

0 ! -#

0

+0 3 ." 0 % "

"

! -

# +0 , F .14%$./++%.%;6$5$6%+3%$!

#

) %%"# "( $$!(!$$-2$-+%"4

6-15/..%"$$5.$-/++%"/5-/

) %%"# "( $(!$.-%5; 3 3 $ !2 " $ $#

2I1%I!28 #

/5.-% $-./%$5.%; % ,

3 6 &>"=$F"%-8"1"2F09"+%;%."3;+6

:%/"2;6$:8I/.I$+&'"6

;$3"$:"$;3 %"8;2B:%"-;3

$ &$!"!/$"'!( %

N

! ($++/3$.;.14%$./++%./

.##%$)"/$ !$7 ; %%

% "

&@@?: 5 2

4 4 2" 5 &@@?: $3$ &@@@: %/$ 8"&@@@:1/3=-"5&@@@:$3$4')))7 /35$5 5" /5-/ " $54-/5% 6" 6

8 % 2 -

.IKKI-/L5%'))':@>;&);'>**'7 /5-/ " /35$5 5" 65/++% +" G K4 l-'))>:>)7 $ F

G K K

K%L4'))E:'&;&)*&&A7 5" $ " 6

+" K K

; 8

N8 %-

.|-/L5%')&&:&)A;&&A

82


Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in PiemonteScheda: 3.005 Alleg.

#5

)56

!"#$%*)!

#$(($+$,!"%$$!($ ,(( ;$# \

6#\;\

:\'#

N#\0

'"($"%$-'( *$$.%("($"(($% "

" $ /0

;!F#

!,#%" ;!F#

%

! # % 0

-/ !" " " " # + % ,

" % " " " "

% a " 0 1

, ?) b"

/0 &) * ' ! # 4 , 45$ aF ! - *) F A # % 45$ p

a " ! # % p f>b ')b 1

%

&)

"

*

+

5 ,

0

)"%"*$('$+0

-/"

N

83



" , 0 &A< "

2"

0 -/" -/' -/A /0 0 ."

! e&) : {j &) :

e &) :

{j &) # 8

86. " {j &)

("( *$"+"!/"'!( "%0121323413/0

" 0

/0

0

% . 0 5

" % ! A)&

'))*-;2/$5%2% $.6%+3%% %2+%$.% 5/++$ 4/./B%5/ 86. /4 /54%$ 4/3+%$4/52%$$5B$.%+

86. %

( ! # !

NF# a

86.

0

% "

0 ! F" $" %

#

0""+,,

$-$../-%.%9/+%5%$.+3%9/4/++$5/+$%$/--$.$1

"

"

I I + ,

" "

a 0

" + " "

0

N

;8

N-.&% -/"

.

4 - !

N.

) %%"# "( $$!(!$5/35$5"/5-/

) %%"# "( $(!$.-%5; 2 -" $

! A)&

84



/5.-% $-./%$5.%; %." 3: %/" 2; 3 : 8 I/ .I %"6

;23:"$;:%"-;-

$ &$!"!/$"'!( +

0

0 /

.##%$)"/$ !$

0

86.

8

86.

8

85



) 5 5

)55

!"#$%*,5 !)

) *$!"'!(

#$(($+$,!"%$$!($ ,((

"

9

9

" "

"

'#

F 9

9

9

"

" "

A#

9

9 K

%

'"($"%$-'( *$$.%("($"(($ .

! 5.; 5N

# + ,

% ." ." /- !6" % -#" ! #" 8 /

'* E)

+ , "

&))))) " *)))) %

;

!9K %%" 6 # +

9 {j A*" + 9

N

5

,

9 .

A + , 4 - %5' a

A +

: 4- ,

9 p ,

a :

! #

" " "

N

'# 5

5. ,

" "

!"

#

+

"

" " "

"

-5$ /E /<

&E CE< 9 "

+

86



9 & "

+ %5 F +

%5

F %5 F +

p F

A#

" / 9.$

5. F

)"%"*$('$')&A;&

N

"

9' $

" J

$

-5$&E(CE



9

9 ,

9"

!"

"

9 #

9 5

')&'

. ,

9.$ ,

9 /

/ 9.$ !9

# F

"

')&A 2

- -

43- 9

) %%"# "( $$!(!$+ 4/ 2$-" $ 3%++%." + 3%-4$5"

3%16%+$." +$-$." /

2$5%5%"82/-+/..%"-

-%BB+"5/35$5

$ &$!"!/$"'!( 8 - Z5

[ . 2

! #

1/! 9 # >

2

-5$

2

$+

! (.14% 21+.%/5.-%% + 5. , !3-# + -5$ , 3- ! $1+ - /#: 3 - ,

&E(CE*;''&7 $-6D5 2" -5 3" 2/%L/- L+2" 5$1+/- . KK N 9

!# +'))@:&);@A*E7 -5 3" 3%-3%-% " $-BB% 8" 58-.%5% 2" 4$++$ $+2$ " 4/+ 2%.- $" 39%-%539/++ 6"3%-+$54 " 3%++%. $" 4/ 2$- +" 5$+45% " %/-..% " -%BB+ -" 9%5$3+%$ " B-B% 2"B$$ 2" /35$5 5" 1B%C L 5N .

!5.# =F3 /K

;

+')&):&&;'>@'*@7 4" - 3" 8 % ; / /')&):A>;*EE&7 8 " - 3 . 9% N !/# $%4')&):'>;'**7 $K 2" ]J 4" K 2" 2" FK L" +K " 3

2" 6 +" - 3" = 5"6 L" ` D+" 4K +" 6 L" $N +" 3 $" . 2" 2 L /1-3%5')&&9

%L')&':&A&;&@E@?'7 2 " 3

. $" 4 2 +" 2"

$" 6 " /" 5" - 3-

9

1/')&':AE;??@>

89

Pre

e programma di attività 2013 2012 - cpo.it · 3.004 Monitoraggio di indicatori di qualità della...

Documents

Transcript of e programma di attività 2013 2012 - cpo.it · 3.004 Monitoraggio di indicatori di qualità della...